METAL-FREE SYNTHESIS of 2,3-DIHYDROQUINAZOLINONE DERIVATIVES USING 5-SULFOSALICYLIC ACID AS an ORGANOCATALYST Chandrakant D

Total Page:16

File Type:pdf, Size:1020Kb

METAL-FREE SYNTHESIS of 2,3-DIHYDROQUINAZOLINONE DERIVATIVES USING 5-SULFOSALICYLIC ACID AS an ORGANOCATALYST Chandrakant D Bhenki et al RJLBPCS 2020 www.rjlbpcs.com Life Science Informatics Publications Original Research Article DOI: 10.26479/2020.0602.04 METAL-FREE SYNTHESIS OF 2,3-DIHYDROQUINAZOLINONE DERIVATIVES USING 5-SULFOSALICYLIC ACID AS AN ORGANOCATALYST Chandrakant D. Bhenki1, 2*, Shrikrishna S. Karhale1, Kiran N. Patil3, Vasant B. Helavi1 1. Department of Chemistry, Rajaram College, Kolhapur, (M.S.), India. 2. Department of Chemistry, Shri S. H. Kelkar College, Devgad, Sindhudurg, (M.S.), India. 3. Department of Chemistry, Dr.Ghali College, Gadhinglaj, Kolhapur, (M.S.), India ABSTRACT: An efficient, selective and green protocol for the synthesis of 2,3- dihydroquinazolinone derivatives developed by the reaction of 2-aminobenzamide and aromatic aldehydes under metal-free conditions using 5-sulfosalicylic acid (5-SSA) as an organocatalyst in ethanol - water (1:1,v/v) system. The main advantages of this procedure include the use of an organocatalyst, practical simplicity, high yields, eco-friendly solvent, atom economy and ease of isolation of the product. Keywords: Organocatalyst, Metal-free synthesis, High atom economy,2,3-dihydroquinazolinones, Green protocol etc. Article History: Received: March 10, 2020; Revised: March 29, 2020; Accepted: April 15, 2020. Corresponding Author: Mr. Chandrakant D. Bhenki* Department of Chemistry, Shri S. H. Kelkar College, Devgad, Sindhudurg, Pin.: 416613, (M.S.), India, Email address: [email protected] 1.INTRODUCTION In several important natural and synthetic organic derivatives, the quinazolinone ring is observed.[1] It is a useful privileged scaffold for library design and drug discovery applications. [2] 2, 3-dihydroquinazolinone derivatives are reported as an anticancer, [3] antihypertensive agent.[4] 2, 3-dihydroquinazolinone derivatives having a broad range of potential biological and pharmacological activities,[5]as well as their importance in the preparation of drug molecules and natural product, therefore they becomes an important class of fused heterocycles.[6] Drugs having a quinazolinone ring are Diproqualone which is used as anti inflammatory and Methaqualone is © 2020 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications 2020 March – April RJLBPCS 6(2) Page No.52 Bhenki et al RJLBPCS 2020 www.rjlbpcs.com Life Science Informatics Publications used as antimalarial and currently being used for the assessment of the abuse liability of sedative - hypnotic drugs [7] as shown in Fig.1. O O N OH N OH N N Diproqualone Methaqualone Fig. 1. Biologically important scaffolds having quinazolinone skeleton. The increasing attention during the last decades for environmental protection has led both modern academic and industrial groups to develop less hazardous synthetic methodologies for organic synthesis. For the synthesis of biologically active organic molecules employing environmentally friendly organocatalyst has received much attention. Recently Hamzeh et al. found that the 5-SSA is used as a green catalyst for the synthesis of 1-amidoalkyl-2-naphthol by the reaction of 2- naphthol, substituted aldehyde and benzamide or acetamide. [8] Organocatalysts are simple organic molecules able to promote a wide range of chemical transformations.[9,10] They also typically have prominent characteristics including metal-free environment, relatively simple functionality, air stability, low cost, low toxicity and biological friendliness. [11,12] Search for more suitable preparation of 2,3-dihydroquinazolinone continues today. A particularly, catalyst suchasKAl(SO4)2.12H2O,[13]Fe3O4/Chitosen,[14]Al(H2PO4)3,[15]Zn(PFO)2,[16]SbCl3,[17](CeSO 4)2.4H2O,[18]SiCl4,[19]MWCNTS,[20]T3P,[21]Ionicliquid,[22]Tannicacid,[23]PEG400,[24]TBAB n ,[25]H-ZSM-5nanozeolite,[26]Fe3O4@SiO2-imid-PMA ,[27] etc. have been known to achieve this transformation. All these conventional methodologies have come across certain drawbacks such as transition metal catalyst, prolonged reaction times, tedious catalysts preparation and workup, use of toxic solvents. However the development of an efficient method , easy work up procedure, simple, environmentally benign protocol using a water soluble, metal-free catalyst and green solvent for the synthesis of quinazolinone derivatives is still desirable and in demand.[28] The development of organocatalyzed reactions in which the reactions are catalyzed by organic molecules is an important area for green synthesis. The use of water as the solvent increases the rate of the chemical reactions and also decreases the risk of organic solvent. Aqueous ethanol mixture for the reaction medium has worked wonderfully in many instances.[29] This offers a homogenous medium for many reactions and provides rate accelerations .[ 30] In continuation of our research in the development of environment-friendly methodologies for the synthesis of bioactive heterocyclic moieties. [31-34] In current work, we reported a novel methodology for the synthesis of 2,3-dihydroquinazolinone by ring closure of 2-aminobenzamide with substituted aromatic aldehydes, in the presence of 20 mol% 5-SSA in aqueous ethanol. To the best of our knowledge we develop this green methodology for the synthesis of an important class of fused heterocycles from cheap and easily available starting materials by employing cheap and easily © 2020 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications 2020 March – April RJLBPCS 6(2) Page No.53 Bhenki et al RJLBPCS 2020 www.rjlbpcs.com Life Science Informatics Publications available 5-SSA as an efficient organocatalyst in a green medium. 2. MATERIALS AND METHODS Experimental 5-sulfosalicylic acid (Spectrochem), 2-aminobenzamide (Thomas Baker), and aromatic aldehydes (Spectrochem and Thomas Baker) were used as received. All the reactions were carried out in dried glassware under an open atmosphere. The melting points of all purified synthesized compounds were recorded using a hot paraffin bath and are uncorrected. The IR spectra were recorded in the frequency range 500-4000 cm-1, on Alpha100508 FT-IR spectrometer. The NMR spectra were recorded on a Bruker Avance (400 MHz for 1H NMR and 100 MHz for 13C NMR) spectrometer using DMSO as solvent using Tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) are expressed in parts per million (ppm) values with the TMS as an internal reference, and coupling constants (J) are expressed in hertz (Hz). The Mass spectra of the purified product were recorded on a HRMS. General procedure for the synthesis of 2,3-dihydroquinazolin-4(1H)-one derivatives In 25 ml RB flask, a mixture of 2-aminobenzamide (1 mmol), aryl aldehyde (1 mmol), and 5- sulfosalicylic acid (20 mol%) in ethanol- water (1:1, v/v; 5 mL) was stirred at 80°C for a specified time (150 min – 240 min.) (Scheme 1 ) . Upon completion of the reaction as indicated by TLC, the reaction mixture was allowed to cool at room temperature and water (5 mL) was added and stirred continuously until solid was obtained in the reaction flask. The resultant solid was filtered, washed with water and then dried. The solid was recrystallized by pet ether: ethyl acetate (70:30, v/v). All the resulting products were pure and characterized by spectroscopic techniques. O O CHO NH NH 2 5-SSA (20mol%) + o N NH2 Ethanol:Water, 80 C R H R Scheme 1: Synthesis of 2,3-dihydroquinazolinone derivatives Spectral data of representative compounds 2-(4-nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one (3b) (Table 3, entry 2) 1 Yellow Solis, Mp:198-199 °C, Yield = 92%, H NMR (400 MHz, CDCl3):δ = 6.74 - 6.76 (d, J = 8.4 Hz, 1 H), 8.22-8.25 (m, 1 H), 7.23-7.30(m, 2 H), 6.65-6.69 (m, 1 H), 5.89 (s, 1 H), 7.71- 13 7.74(d, J = 8.8 Hz, 1 H), 8.48 ( s, 1 H), 7.61 ( s, 1 H), CNMR (100 MHz, CDCl3): δ = 163.2, 149.2, 147.2, 147.1, 133.4, 127.3, 123.5, 177.4, 165.25. IR (KBr) cm–1: 3367, 3289, 3027, 1646, 1600, MS (ESI): m/z 270 [M +]. 2-(4-bromophenyl)-2,3-dihydroquinazolin-4(1H)-one (3c)( Table 3,entry 3) 1 Yellow Solid,Mp.196-197 °C, Yield =90%, H-NMR (400 MHz, CDCl3): δ = 7.56-7.25 (m, 5 H), 6.72-6.74 (d, J =8.0 Hz, 2 H), , 6.64-6.68 (m, 1 H), 5.74 (s, 1 H), 8.29 ( s, 1 H), 7.11, ( s, 1 H), 13C- © 2020 Life Science Informatics Publication All rights reserved Peer review under responsibility of Life Science Informatics Publications 2020 March – April RJLBPCS 6(2) Page No.54 Bhenki et al RJLBPCS 2020 www.rjlbpcs.com Life Science Informatics Publications NMR (100 MHz, CDCl3):δ=163.4, 147.5, 141.0, 133.3, 131.1, 129, 127.3, 121.4, 117.2, 114.4, 65.75, IR (KBr): 3367, 3282, 3038, 1647, 1603,MS (ESI): m/z 303 [M +]. 3. RESULTS AND DISCUSSION Initially, we chose a reaction of 2-aminobenzamide with 4-nitrobenzaldehyde as a model reaction in order to investigate the effects of solvent, temperature and amount of catalyst on the yield of the product.(Scheme 2) O CHO O NH 2 5-SSA, Ethanol:H2O NH NH + o 2 80 C N H NO2 NO2 Scheme 2: Synthesis of 2-(4-Nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one (3b). For this purpose, we have screened several solvents such as toluene, THF, methanol, water, ethanol, acetonitrile, methylene dichloride, ethanol- water (1:1) etc. It was observed that the non- polar solvents such as toluene gave only moderate yields of the products (55%) and the polar solvents (ethanol, acetonitrile, methylene dichloride and methanol) give a much better yield than toluene, THF also gave a good yield for the reaction. In pursuance of making this protocol greener and economical, it was found that ethanol-water (1:1) acts more superior than other solvents, and gave excellent yield (92%) for this reaction (Table 1, Entry 3).
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • The Two Tonttituntivi Da Ti on and Main
    THETWO TONTTITUNTIVIUS 20180264013A1 DA TI ON AND MAIN ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0264013 A1 DILL ( 43 ) Pub . Date : Sep . 20 , 2018 ( 54 ) COMPOSITION AND METHODS FOR Publication Classification TREATING SLEEP DISORDERS (51 ) Int. CI. A61K 31 /60 (2006 . 01 ) ( 71 ) Applicant: WELLESLEY A61K 31 / 4025 ( 2006 .01 ) PHARMACEUTICALS , LLC , A61K 45 / 06 ( 2006 .01 ) Newtown , PA (US ) A61K 31 /616 ( 2006 . 01 ) A61K 31/ 4725 ( 2006 . 01 ) (72 ) Inventor : David A . DILL , Newtown , PA (US ) A61K 31 / 46 (2006 .01 ) A61K 31/ 405 ( 2006 .01 ) A61K 9 / 00 ( 2006 .01 ) (21 ) Appl. No. : 15 /985 ,315 A61K 31 /216 ( 2006 . 01 ) A61K 31 / 192 (2006 . 01 ) ( 22 ) Filed : May 21 , 2018 A61K 31 / 19 ( 2006 .01 ) A61K 31 / 167 (2006 . 01 ) A61K 31 / 12 ( 2006 .01 ) Related U . S . Application Data (52 ) U . S . CI. @(63 ) Continuation - in -part of application No. 14 / 172, 649 , CPC . .. .. A61K 31 /60 (2013 . 01 ) ; A61K 31 /4025 filed on Feb . 4 , 2014 , which is a continuation of ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; A61K application No . 13 / 847 , 927 , filed on Mar. 20 , 2013 , 31 /616 ( 2013 . 01 ) ; A61K 31 /4725 ( 2013 .01 ) ; now Pat . No . 8 ,685 , 453 , which is a continuation of A61K 31/ 46 ( 2013 .01 ) ; A61K 2300 /00 application No. 13 / 560 ,607 , filed on Jul. 27 , 2012 , ( 2013 .01 ) ; A61K 9 /0002 ( 2013 . 01 ) ; A61K now Pat. No. 8 ,445 , 015 , which is a continuation of 31 / 216 ( 2013 .01 ) ; A61K 31/ 192 ( 2013 . 01 ) ; application No. 13 / 487, 348 , filed on Jun .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3H)-One(Thione) Derivatives with DFT Study
    molecules Article Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3H)-one(thione) Derivatives with DFT Study Amira A. El-Sayed 1, Mahmoud F. Ismail 1 , Abd El-Galil E. Amr 2,3,* and Ahmed M. Naglah 2,4 1 Department of Chemistry, Faculty of Science, Ain Shams University, 11566 Abbassia, Cairo 11566, Egypt; [email protected] (A.A.E.-S.); [email protected] (M.F.I.) 2 Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; [email protected] 3 Applied Organic Chemistry Department, National Research Center, Cairo, Dokki 12622, Egypt 4 Peptide Chemistry Department, Chemical Industries Research Division, National Research Centre, Dokki, Cairo 12622, Egypt * Correspondence: [email protected]; Tel.: +966-543074312 Academic Editor: Qiao-Hong Chen Received: 5 October 2019; Accepted: 20 October 2019; Published: 21 October 2019 Abstract: The current study was chiefly designed to examine the antiproliferative and antioxidant activities of some novel quinazolinone(thione) derivatives 6–14. The present work focused on two main points; firstly, comparing between quinazolinone and quinazolinthione derivatives. Whereas, antiproliferative (against two cell lines namely, HepG2 and MCF-7) and antioxidant (by two methods; ABTS and DPPH) activities of the investigated compounds, the best quinazolinthione derivatives were 6 and 14, which exhibited excellent potencies comparable to quinazolinone derivatives 5 and 9, respectively. Secondly, we compared the activity of four series of Schiff bases which included the quinazolinone moiety (11a–d). In addition, the antiproliferative and antioxidant activities of the compounds with various aryl aldehyde hydrazone derivatives (11a–d) analogs were studied.
    [Show full text]
  • The Effortless Sleep Method: Cure for Insomnia
    Sleeping Pills: An Introduction 1 1 Sleeping Pills: An Introduction What Are Sleeping Pills? Most sleeping pills are “sedative hypnotics.” That’s a specific class of drugs used to induce and/or maintain sleep. Sedative hypnotics include benzodiazepines, barbiturates, and various hypnotics. SLEEPING PILL ABUSE: ITS SIGNS AND SYMPTOMS A number of people underestimate the powerful grip sleeping pills like Ambien or Sonata can have over someone’s life and the dangers of abusing these drugs. 2 The Effortless Sleep Method: Cure for Insomnia... Many people abusing sleeping pills experience memory and concentration problems. Some of the signs of sleeping pill abuse include: • Slurred speech • Uncoordinated movements • Unsteady gait • Inability to focus • Impaired memory • Unusual euphoria. SLEEPING PILLS: ITS MAIN DANGERS Both the immediate and long-term dangers of sleeping pill abuse are enough for most people to exercise caution when using them. However, many people aren’t aware of the dangers of these medications. The dangerous effects of sleep medications range from seizures to depressed breathing. Some people also experience allergic reactions from sleeping pills that can cause difficulty breathing, chest pain, nausea and swelling. Though rare, people who use sleeping pills may even develop parasomnias. Parasomnias are defined as sleep disorders that include behaviors like sleep-walking, sleep-eating, sleep-sex, sleep- driving and other potentially dangerous sleep-related activities. The immediate dangers of sleeping pills range from minor fatigue to coma. Some of these side effects can even lead to deadly overdoses, casting light on the true dangers of sleeping pills. Common symptoms of sleeping pill abuse are: • Dizziness • Dry mouth • Difficulty with coordination • Daytime drowsiness • Memory loss • Unusual dreams • Itching and swelling Sleeping Pills: An Introduction 3 • Lightheadedness • Depressed breathing rate.
    [Show full text]
  • Quinazolinone Derivatives As An
    inal chem ic is d t Abulkhair et al., Med Chem (Los Angeles) 2016, 6:9 e r M y Medicinal chemistry DOI: 10.4172/2161-0444.1000404 ISSN: 2161-0444 t Research Article Open Access Molecular Docking, Synthesis and Biological Evaluation of Some Novel 2-Substituted-3-allyl-4(3H)-quinazolinone Derivatives as Anticonvulsant Agents Hamada S Abulkhair1, Kamal M El-Gamal1,2, Khaled El-Adl3* and Mohamed F Fadl4 1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt 2Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy and Pharmaceutical Industries, Delta University, Mansoura, Egypt 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt 4Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt Abstract A new series of 2-substituted-3-allyl-4(3H)-quinazolinone derivatives (4a-e-8a-d) were synthesized and evaluated for their anticonvulsant activity against pentylenetetrazole (PTZ)-induced seizures and maximal electroshock test in mice and compared with the reference drugs methaqualone and sodium valproate. The neurotoxicity was assessed using rotarod test. The molecular modeling was performed for all synthesized compounds to predict their binding affinity towards GABA-A receptor as a proposed mode of their anticonvulsant activity. The data obtained from the molecular docking was strongly correlated with that obtained from the biological screening which revealed that; compounds 4c, 4b and 4d showed the highest binding affinities towards GABA-A receptor and also showed the highest anticonvulsant activities in experimental mice with relatively low neurotoxicity and low toxicity in the median lethal dose test when compared with the reference drugs.
    [Show full text]
  • WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61L 24/04 (2006.01) A61K 9/127 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/US20 13/0406 19 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 10 May 2013 (10.05.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/646,227 11 May 2012 ( 11.05.2012) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/669,577 9 July 2012 (09.07.2012) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 61/785,358 14 March 2013 (14.03.2013) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: MEDICUS BIOSCIENCES, LLC [US/US]; ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]